Printer Friendly

IOMED SHOWS SAFETY OF IONTOPHORESIS IN OPHTHALMIC APPLICATIONS.

IOMED, Inc. (AMEX: IOX), Salt Lake City, has successfully completed a key preclinical safety study involving transscleral iontophoresis.

In a presentation given at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), IOMED's researchers disclosed that an iontophoretic method of delivery did not affect intraocular pressure or retinal function.

The presentation, entitled Effects of In Vivo Ocular Iontophoresis on Rabbit Eye Structure and Retinal Function reported results using IOMED's new prototype ophthalmic hydrogel iontophoretic drug delivery electrodes. The research was conducted to evaluate possible effects on visual function using standard ophthalmologic tests, including ERG, and to evaluate possible eye irritation. Results showed that visual function was not affected adversely at current levels even higher than those anticipated for treatments and that only mild irritation was seen on the eye surface at treatment sites.

"We are very encouraged by this research," commented Steven L. Hamilton , IOMED's executive vice president of Business Development. "These research results indicate that iontophoresis is a potential new noninvasive method of delivering drugs to the eye. The results, along with the preclinical research announced recently regarding our ability to deliver both large and small molecules to the retina of the eye, will provide strong support for IOMED's ophthalmic research."

IOMED, Inc. is a leader in the research, development and manufacture of iontophoretic drug delivery systems, which are marketed to healthcare providers worldwide. Iontophoretic drug delivery involves the transport of water-soluble ionic drugs into and through skin and other body tissues using a mild electrical current. IOMED also conducts advanced research for local and systemic delivery of ionic pharmaceutical compounds to treat various medical conditions.

For more information, visit www.iomed.com or call 801/975-1191.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:IOMED SHOWS SAFETY OF IONTOPHORESIS IN OPHTHALMIC APPLICATIONS.
Publication:Biotech Equipment Update
Geographic Code:1USA
Date:Jun 1, 2000
Words:282
Previous Article:LUNAR GETS FDA 510K CLEARANCE FOR LATERAL VERTEBRAL ASSESSMENT.
Next Article:ENDOSONICS GETS FDA APPROVAL TO BEGIN RADIATION DEVICE TRIALS.
Topics:


Related Articles
IOMED INTRODUCES NUMBY STUFF FOR PAINLESS NEEDLE INSERTION
IOMED INTRODUCES NEW DOSE CONTROLLER.
SUNRISE LTK SYSTEM PMA SCHEDULED FOR FDA ADVISORY PANEL REVIEW.
ReAble to acquire IOMED for $22m.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters